60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
Investing.com - TD Cowen has reiterated a Buy rating on UCB SA (BR:UCB) with a price target of EUR300.00, highlighting the company’s execution on product launches.
The research firm emphasized that the "Bimzelx inflection is just beginning" and noted UCB is performing well with launches across multiple indications including psoriasis (PSO), psoriatic arthritis/ankylosing spondylitis (PSA/AS), and particularly hidradenitis suppurativa (HS).
TD Cowen specifically pointed to HS growth dynamics as supporting UCB’s strategy to establish Bimzelx as a "long-term incumbent in a large market."
The EUR300 price target represents approximately 21 times the firm’s 2027 estimated earnings per share and reflects what TD Cowen describes as "Bimzelx’s EUR6B+ opportunity with clear upside."
The research firm suggested UCB should be considered a "core 2026 holding for the durable earnings growth" it may provide to investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.